An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis; Inflammatory Myopathy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Sjogren ' s Syndrome Interventions: Other: YTS109 Sponsors: China Immunotech (Beijing) Biotechnology Co., Ltd.; Shanghai Changzheng Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
Negative Antiphospholipid Syndrome: a Multicentric Study
Conditions: Antiphospholipid Syndrome; Seronegative Antiphospholipid Syndrome Interventions: Other: Diagnostic accuracy Sponsors: Italian Society for Rheumatology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus (SLE); Sjogren ' s Syndrome; Systemic Sclerosis; Inflammatory Myopathy; ANCA Associated Vasculitis; Antiphospholipid Syndrome Interventions: Biological: Anti-CD19-CD3E-CAR-T cells Sponsors: Shanghai Changzheng Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
Conditions: Antiphospholipid Syndrome Interventions: Biological: blood withdrawal Sponsors: Centre Hospitalier Universitaire, Amiens Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Conditions: Antiphospholipid Syndrome (APS); Bullous Pemphigoid (BP); Beh çet ' s Syndrome (BS); Dermatomyositis (DM); Immune-mediated Necrotizing Myopathy (IMNM); Immune Thrombocytopenia (ITP) Interventions: Drug: RAY121 Sponsors: Chugai Pharmaceutical Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Evaluation of Endothelial Dysfunction Using the " Flow Mediated Dilation " Test in a Population of Chronic Renal Failure Patients at Different Stages, and Evaluation of the Role of Antiphospholipid Antibodies
Conditions: Chronic Renal Failure Interventions: Procedure: Urine sampling; Procedure: Blood sampling; Device: Flow mediated dilatation test Sponsors: Brugmann University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Effect of Telitacicept on Antibody Titers in Primary APS Patients
Conditions: Antiphospholipid Syndrome (APS) Interventions: Drug: Telitacicept; Drug: SOC Sponsors: Ruijin Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Arteriovenous Fistula Maturation in Hemodialysis Patients With or Without Positive Antiphospholipid Antibodies
Conditions: Chronic Kidney Diseases Interventions: Other: Data collection in medical records; Other: Blood sampling Sponsors: Brugmann University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
Conditions: Antiphospholipid Syndrome; Ischemic Stroke; Transient Ischemic Attack; Cerebrovascular Disease; Cardiovascular Diseases; Major Bleed Interventions: Drug: Antiplatelet Drug; Drug: Warfarin Sponsors: Seoul National University Hospital; Samjin Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 16, 2023 Category: Research Source Type: clinical trials
